Key result
Administration of a neutralizing S100a9 antibody prevented angiotensin II infusion-induced nuclear factor-κ B activation, inflammatory cell infiltration, cytokine production, fibrosis, and hypertrophy.
Why the study?
Does neutralizing S100a9 antibody prevent angiotensin II-induced cardiac inflammation and injury in preclinical models?
Does neutralizing S100a9 antibody prevent angiotensin II-induced cardiac inflammation and injury in preclinical models?
Neutrophil-produced S100a8/a9 acts as an initial proinflammatory factor triggering cardiac inflammation and injury during acute hypertension, and its neutralization prevents these effects.
S100a9 neutralization attenuates cardiac injury in angiotensin II mouse models; hypothesis-generating for human hypertension trials.
Angiotensin II induces cardiovascular injury, in part, by activating inflammatory response; however, the initial factors that trigger the inflammatory cascade remain unclear. Microarray analysis of cardiac tissue exposed to systemic angiotensin II infusion revealed that extracellular heterodimeric proteins S100a8/a9 were highly upregulated. The increase in S100a8/a9 mRNA of CD11b(+)Gr1(+) neutrophils isolated from both the peripheral blood and heart was highest on day 1 of angiotensin II infusion and decreased to baseline at day 7. Immunostaining showed that S100a8/a9 was primarily present in infiltrating CD11b(+)Gr1(+) neutrophils in the heart. The receptor for advanced glycation end products, an S100a8/a9 receptor, was expressed in cardiac fibroblasts (CFs). Microarray analysis and Bio-Plex protein array showed that treatment of CFs with recombinant S100a8/a9 activated multiple chemokine and cytokines released. Luciferase reporter assay indicated S100a8/a9-activated nuclear factor-κ B pathway in CFs. Consequently, recombinant S100a8/a9-treated CFs promoted migration of monocytes and CFs, whereas neutralizing S100a9 antibody blocked S100a9 or receptor for advanced glycation end products-suppressed cellular migration. Finally, administration of a neutralizing S100a9 antibody prevented angiotensin II infusion-induced nuclear factor-κ B activation, inflammatory cell infiltration, cytokine production, subsequent perivascular and interstitial fibrosis, and hypertrophy in heart. Our findings identify neutrophil-produced S100a8/a9 as an initial proinflammatory factor needed to trigger inflammation and cardiac injury during acute hypertension.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2014) studied Angiotensin II-induced cardiac inflammation and injury. Neutralizing S100a9 antibody was evaluated on Nuclear factor-κ B activation, inflammatory cell infiltration, cytokine production, fibrosis, and hypertrophy. Administration of a neutralizing S100a9 antibody prevented angiotensin II infusion-induced nuclear factor-κ B activation, inflammatory cell infiltration, cytokine production, fibrosis, and hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: